83 results
Page 2 of 5
8-K
EX-99.1
tmzqszy aetn
12 Aug 22
Axcella Reports Second Quarter Financial Results and Provides Business Update
8:11am
8-K
9o1x9fy3ma
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
8-K
EX-99.2
5mziyp09 x6
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
8-K
EX-99.1
0uprhfhem3vuy2
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
8-K
EX-99.1
h1zpl
26 May 22
Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio
8:12am
8-K
EX-99.1
r1duufjf
5 May 22
Axcella Reports First Quarter Financial Results and Provides Business Update
7:41am
8-K
EX-99.1
stolp6zfgg2nz6
30 Mar 22
Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
8:05am
8-K
EX-10.1
any2axk6f 43mpt9c45
16 Mar 22
Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At the Market
8:30am
424B5
7sqlhwlg7tr x9cnkd
16 Mar 22
Prospectus supplement for primary offering
8:00am
8-K
EX-99.1
zuemfdo2 1w167j8
7 Feb 22
Axcella Therapeutics Announces Appointment of New Chief Financial Officer
4:00pm
8-K
EX-99.1
8yq6 qeyj
10 Jan 22
Other Events
8:00am
8-K
EX-99.1
c0j0caiojb5q
7 Dec 21
Departure of Directors or Certain Officers
6:15am
8-K
EX-99.1
tfnxf4fe1 vj7qe
10 Nov 21
Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials
8:08am
8-K
EX-10.1
f13gv3o791md2zam on
7 Sep 21
Entry into a Material Definitive Agreement
4:16pm